USANA HEALTH SCIENCES, INC. Deferred Tax Assets, Operating Loss Carryforwards, Foreign
USANA HEALTH SCIENCES, INC. (USNA) had Deferred Tax Assets, Operating Loss Carryforwards, Foreign of $2.65 million as of 2026-01-03, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign · last filed 2026-03-16
- 2026-01-03: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $2.65M.
- 2024-12-28: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $2.28M.
- 2023-12-30: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $1.89M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $1.67M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Foreign |
|---|---|
| 2026-01-03 | $2.65M 10-K · filed 2026-03-16 |
| 2024-12-28 | $2.28M 10-K · filed 2025-03-12 |
| 2023-12-30 | $1.89M 10-K · filed 2024-02-27 |
| 2022-12-31 | $1.67M 10-K · filed 2023-02-28 |
| 2022-01-01 | $1.33M 10-K · filed 2022-03-01 |
| 2021-01-02 | $2.23M 10-K · filed 2021-03-02 |
| 2019-12-28 | $4.90M 10-K · filed 2020-02-25 |
| 2018-12-29 | $4.30M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |